Omalizumab for Chronic Urticaria
To the Editor: Maurer et al. (March 7 issue) 1 report the results of a phase 3 trial of omalizumab for the treatment of urticaria. Figure 1 of their article shows that withdrawals from the study because of “disease progression” occurred only in patients who received omalizumab; there were no withdra...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2013-06, Vol.368 (26), p.2527-2530 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2530 |
|---|---|
| container_issue | 26 |
| container_start_page | 2527 |
| container_title | The New England journal of medicine |
| container_volume | 368 |
| creator | Wu, Keith Long, Heather Benelli, Elisa Ventura, Alessandro Altman, Matthew C Naimi, David R Maurer, Marcus Rosén, Karin Hsieh, Hsin-Ju |
| description | To the Editor:
Maurer et al. (March 7 issue)
1
report the results of a phase 3 trial of omalizumab for the treatment of urticaria. Figure 1 of their article shows that withdrawals from the study because of “disease progression” occurred only in patients who received omalizumab; there were no withdrawals due to disease progression in the placebo group. Furthermore, the percentage of patients who withdrew due to disease progression correlated with the dose of omalizumab (1% in the 75-mg group, 4% in the 150-mg group, and 8% in the 300-mg group); this suggests that omalizumab may itself, paradoxically, contribute to . . . |
| doi_str_mv | 10.1056/NEJMc1305687 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1372697527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1372697527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5355-8cd7345bcfed9d66faeccf675bafb7fa8913a02d085284a9f9b242d92cbbf6373</originalsourceid><addsrcrecordid>eNqN0TtPwzAUBWALgWgpbMwoEgwMBPx2PKKqvFToQufIdmyRKk7Abgb49bi0IIQYepd7h09nuAeAYwQvEWT86mny8GgQSWchdsAQMUJySiHfBUMIcZFTIckAHMS4gGkQlftggEkBMcNyCLKZV0390XulM9eFbPwSurY22Twsa6NCrQ7BnlNNtEebPQLzm8nz-C6fzm7vx9fT3DDCWF6YShDKtHG2khXnTlljHBdMK6eFU4VEREFcwYLhgirppMYUVxIbrR0ngozA-Tr3NXRvvY3L0tfR2KZRre36WCIiMJeC4a0ppXRbmt6xNeUs0dM_dNH1oU3v-VKIsxUcgYu1MqGLMVhXvobaq_BeIliuqit_V5f4ySa0195WP_i7qwTO1sD7WLZ24f_P-QQ3cZrX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1372165697</pqid></control><display><type>article</type><title>Omalizumab for Chronic Urticaria</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Wu, Keith ; Long, Heather ; Benelli, Elisa ; Ventura, Alessandro ; Altman, Matthew C ; Naimi, David R ; Maurer, Marcus ; Rosén, Karin ; Hsieh, Hsin-Ju</creator><creatorcontrib>Wu, Keith ; Long, Heather ; Benelli, Elisa ; Ventura, Alessandro ; Altman, Matthew C ; Naimi, David R ; Maurer, Marcus ; Rosén, Karin ; Hsieh, Hsin-Ju</creatorcontrib><description>To the Editor:
Maurer et al. (March 7 issue)
1
report the results of a phase 3 trial of omalizumab for the treatment of urticaria. Figure 1 of their article shows that withdrawals from the study because of “disease progression” occurred only in patients who received omalizumab; there were no withdrawals due to disease progression in the placebo group. Furthermore, the percentage of patients who withdrew due to disease progression correlated with the dose of omalizumab (1% in the 75-mg group, 4% in the 150-mg group, and 8% in the 300-mg group); this suggests that omalizumab may itself, paradoxically, contribute to . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1305687</identifier><identifier>PMID: 23802529</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Anti-Allergic Agents - therapeutic use ; Antibodies, Anti-Idiotypic - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Asthma ; Dermatitis ; Female ; Humans ; Immunoglobulin E ; Male ; Monoclonal antibodies ; Patients ; Pruritus - drug therapy ; Urticaria ; Urticaria - drug therapy</subject><ispartof>The New England journal of medicine, 2013-06, Vol.368 (26), p.2527-2530</ispartof><rights>Copyright © 2013 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5355-8cd7345bcfed9d66faeccf675bafb7fa8913a02d085284a9f9b242d92cbbf6373</citedby><cites>FETCH-LOGICAL-c5355-8cd7345bcfed9d66faeccf675bafb7fa8913a02d085284a9f9b242d92cbbf6373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1305687$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1372165697?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52360,54042,64361,64363,64365,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23802529$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Keith</creatorcontrib><creatorcontrib>Long, Heather</creatorcontrib><creatorcontrib>Benelli, Elisa</creatorcontrib><creatorcontrib>Ventura, Alessandro</creatorcontrib><creatorcontrib>Altman, Matthew C</creatorcontrib><creatorcontrib>Naimi, David R</creatorcontrib><creatorcontrib>Maurer, Marcus</creatorcontrib><creatorcontrib>Rosén, Karin</creatorcontrib><creatorcontrib>Hsieh, Hsin-Ju</creatorcontrib><title>Omalizumab for Chronic Urticaria</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Maurer et al. (March 7 issue)
1
report the results of a phase 3 trial of omalizumab for the treatment of urticaria. Figure 1 of their article shows that withdrawals from the study because of “disease progression” occurred only in patients who received omalizumab; there were no withdrawals due to disease progression in the placebo group. Furthermore, the percentage of patients who withdrew due to disease progression correlated with the dose of omalizumab (1% in the 75-mg group, 4% in the 150-mg group, and 8% in the 300-mg group); this suggests that omalizumab may itself, paradoxically, contribute to . . .</description><subject>Anti-Allergic Agents - therapeutic use</subject><subject>Antibodies, Anti-Idiotypic - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Asthma</subject><subject>Dermatitis</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin E</subject><subject>Male</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pruritus - drug therapy</subject><subject>Urticaria</subject><subject>Urticaria - drug therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0TtPwzAUBWALgWgpbMwoEgwMBPx2PKKqvFToQufIdmyRKk7Abgb49bi0IIQYepd7h09nuAeAYwQvEWT86mny8GgQSWchdsAQMUJySiHfBUMIcZFTIckAHMS4gGkQlftggEkBMcNyCLKZV0390XulM9eFbPwSurY22Twsa6NCrQ7BnlNNtEebPQLzm8nz-C6fzm7vx9fT3DDCWF6YShDKtHG2khXnTlljHBdMK6eFU4VEREFcwYLhgirppMYUVxIbrR0ngozA-Tr3NXRvvY3L0tfR2KZRre36WCIiMJeC4a0ppXRbmt6xNeUs0dM_dNH1oU3v-VKIsxUcgYu1MqGLMVhXvobaq_BeIliuqit_V5f4ySa0195WP_i7qwTO1sD7WLZ24f_P-QQ3cZrX</recordid><startdate>20130627</startdate><enddate>20130627</enddate><creator>Wu, Keith</creator><creator>Long, Heather</creator><creator>Benelli, Elisa</creator><creator>Ventura, Alessandro</creator><creator>Altman, Matthew C</creator><creator>Naimi, David R</creator><creator>Maurer, Marcus</creator><creator>Rosén, Karin</creator><creator>Hsieh, Hsin-Ju</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130627</creationdate><title>Omalizumab for Chronic Urticaria</title><author>Wu, Keith ; Long, Heather ; Benelli, Elisa ; Ventura, Alessandro ; Altman, Matthew C ; Naimi, David R ; Maurer, Marcus ; Rosén, Karin ; Hsieh, Hsin-Ju</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5355-8cd7345bcfed9d66faeccf675bafb7fa8913a02d085284a9f9b242d92cbbf6373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anti-Allergic Agents - therapeutic use</topic><topic>Antibodies, Anti-Idiotypic - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Asthma</topic><topic>Dermatitis</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin E</topic><topic>Male</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pruritus - drug therapy</topic><topic>Urticaria</topic><topic>Urticaria - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Keith</creatorcontrib><creatorcontrib>Long, Heather</creatorcontrib><creatorcontrib>Benelli, Elisa</creatorcontrib><creatorcontrib>Ventura, Alessandro</creatorcontrib><creatorcontrib>Altman, Matthew C</creatorcontrib><creatorcontrib>Naimi, David R</creatorcontrib><creatorcontrib>Maurer, Marcus</creatorcontrib><creatorcontrib>Rosén, Karin</creatorcontrib><creatorcontrib>Hsieh, Hsin-Ju</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Keith</au><au>Long, Heather</au><au>Benelli, Elisa</au><au>Ventura, Alessandro</au><au>Altman, Matthew C</au><au>Naimi, David R</au><au>Maurer, Marcus</au><au>Rosén, Karin</au><au>Hsieh, Hsin-Ju</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omalizumab for Chronic Urticaria</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2013-06-27</date><risdate>2013</risdate><volume>368</volume><issue>26</issue><spage>2527</spage><epage>2530</epage><pages>2527-2530</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Maurer et al. (March 7 issue)
1
report the results of a phase 3 trial of omalizumab for the treatment of urticaria. Figure 1 of their article shows that withdrawals from the study because of “disease progression” occurred only in patients who received omalizumab; there were no withdrawals due to disease progression in the placebo group. Furthermore, the percentage of patients who withdrew due to disease progression correlated with the dose of omalizumab (1% in the 75-mg group, 4% in the 150-mg group, and 8% in the 300-mg group); this suggests that omalizumab may itself, paradoxically, contribute to . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>23802529</pmid><doi>10.1056/NEJMc1305687</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2013-06, Vol.368 (26), p.2527-2530 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1372697527 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Anti-Allergic Agents - therapeutic use Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Asthma Dermatitis Female Humans Immunoglobulin E Male Monoclonal antibodies Patients Pruritus - drug therapy Urticaria Urticaria - drug therapy |
| title | Omalizumab for Chronic Urticaria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T11%3A04%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omalizumab%20for%20Chronic%20Urticaria&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Wu,%20Keith&rft.date=2013-06-27&rft.volume=368&rft.issue=26&rft.spage=2527&rft.epage=2530&rft.pages=2527-2530&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1305687&rft_dat=%3Cproquest_cross%3E1372697527%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1372165697&rft_id=info:pmid/23802529&rfr_iscdi=true |